Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
Percentage of patients achieving Glycosylated Hemoglobin (HbA1c) < 7% with no severe or
nocturnal hypoglycemic episodes at 6 months
Secondary Objectives:
- Glycosylated Hemoglobin (HbA1c) change from baseline to 6 months
- Insulin glargine dose at 3 and 6 months
- Hypoglycemic episodes (all types)